DE69228698T2 - HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG - Google Patents

HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG

Info

Publication number
DE69228698T2
DE69228698T2 DE69228698T DE69228698T DE69228698T2 DE 69228698 T2 DE69228698 T2 DE 69228698T2 DE 69228698 T DE69228698 T DE 69228698T DE 69228698 T DE69228698 T DE 69228698T DE 69228698 T2 DE69228698 T2 DE 69228698T2
Authority
DE
Germany
Prior art keywords
hbsag
plasmodium
hybrid protein
protein
falciparum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69228698T
Other languages
English (en)
Other versions
DE69228698D1 (de
Inventor
Wilde Michel De
Joseph Smithkline Beecha Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919124390A external-priority patent/GB9124390D0/en
Application filed by GlaxoSmithKline Biologicals SA, SmithKline Beecham Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE69228698D1 publication Critical patent/DE69228698D1/de
Application granted granted Critical
Publication of DE69228698T2 publication Critical patent/DE69228698T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69228698T 1991-11-16 1992-11-11 HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG Expired - Lifetime DE69228698T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919124390A GB9124390D0 (en) 1991-11-16 1991-11-16 Vaccines
US84269492A 1992-02-27 1992-02-27
PCT/EP1992/002591 WO1993010152A1 (en) 1991-11-16 1992-11-11 HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG

Publications (2)

Publication Number Publication Date
DE69228698D1 DE69228698D1 (de) 1999-04-22
DE69228698T2 true DE69228698T2 (de) 1999-09-16

Family

ID=26299880

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228698T Expired - Lifetime DE69228698T2 (de) 1991-11-16 1992-11-11 HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG

Country Status (16)

Country Link
EP (1) EP0614465B1 (de)
JP (2) JP3954643B2 (de)
KR (1) KR100251505B1 (de)
AT (1) ATE177755T1 (de)
AU (2) AU2927892A (de)
CA (1) CA2123612C (de)
DE (1) DE69228698T2 (de)
DK (1) DK0614465T3 (de)
ES (1) ES2129461T3 (de)
GR (1) GR3029717T3 (de)
HK (1) HK1012405A1 (de)
MX (1) MX9206574A (de)
NZ (1) NZ245114A (de)
PT (1) PT101052B (de)
SG (1) SG48390A1 (de)
WO (1) WO1993010152A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0761231B1 (de) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Adjuvantien enthaltende Impfstoffzusammensetzung
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
GB9915204D0 (en) * 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
AU2003244053A1 (en) * 2003-06-03 2005-01-21 Shanghai Centre Of Research And Development Of New Drugs A fusion protein suitable to be expressed high effectively and the production method thereof
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
PL1802336T3 (pl) * 2004-10-14 2012-03-30 Crucell Holland Bv Szczepionki pierwotne/przypominające przeciw malarii
US8119146B2 (en) * 2005-04-18 2012-02-21 Angelica Medina-Selby Expressing hepatitis B virus surface antigen for vaccine preparation
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
BRPI0715581A2 (pt) * 2006-07-18 2013-04-24 Glaxosmithkline Biolog Sa proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
GB0614254D0 (en) * 2006-07-18 2006-08-30 Smithkline Beecham Biolog Vaccine
NZ575273A (en) 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
EP2486938B1 (de) 2006-09-26 2018-05-09 Infectious Disease Research Institute Impfstoffzusammensetzung mit einem synthetischen Adjuvans
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
MX2009009342A (es) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
AR067905A1 (es) 2007-08-13 2009-10-28 Glaxosmithkline Biolog Sa Vacunas
EP2234638A1 (de) * 2007-12-24 2010-10-06 GlaxoSmithKline Biologicals SA Malaria-impfstoffe
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
US9555089B2 (en) 2009-08-18 2017-01-31 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
MX357202B (es) 2012-02-16 2018-06-28 Vlp Therapeutics Llc Composicion de particula tipo virus.
BR112014028476A2 (pt) 2012-05-16 2017-08-01 Immune Design Corp fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
CN104870477B (zh) 2012-10-23 2018-10-09 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
WO2014103608A1 (ja) 2012-12-25 2014-07-03 一般財団法人化学及血清療法研究所 HPV/HBsキメラタンパク質を有効成分とするHPV感染症及び／又はＢ型肝炎用ワクチン
AU2014203873A1 (en) 2013-01-07 2015-07-30 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
US9821046B2 (en) 2013-01-21 2017-11-21 Oxford University Innovation Limited Composition and uses thereof
WO2014140166A2 (en) 2013-03-15 2014-09-18 Glaxosmithkline Biologicals S.A. Vaccine
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
RU2702163C2 (ru) * 2013-06-03 2019-10-04 Влп Терапьютикс, Ллк Вакцины против малярии
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
EP2873728A1 (de) 2013-11-18 2015-05-20 Institut Pasteur Subunit-Impfstoff-Plattform auf Grundlage multimerer Ribonukleoproteine mit Nukleoproteinen eines nichtsegmentierten Negativstrang-RNA-Virus als Träger von heterologen Polypeptiden
AU2014373928C1 (en) 2013-12-31 2020-12-17 Access To Advanced Health Institute Single vial vaccine formulations
EP3177720B1 (de) 2014-08-08 2021-09-22 VLP Therapeutics, Inc. Virusähnliches partikel mit modifiziertem hüllprotein e3
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
PL3188755T3 (pl) 2014-09-01 2021-01-25 International Centre For Genetic Engineering And Biotechnology Szczepionka
KR102532832B1 (ko) 2014-09-11 2023-05-16 브이엘피 테라퓨틱스 인코포레이티드 플라비바이러스 바이러스 유사 입자
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
CN109310773B (zh) 2016-05-16 2022-04-26 传染病研究所 含有tlr激动剂的配制品和使用方法
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
BE1025160B1 (fr) 2016-12-07 2018-11-26 Glaxosmithkline Biologicals Sa Nouveau procédé
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
US20210162042A1 (en) 2017-05-30 2021-06-03 Glaxosmithkline Biologicals S.A. Novel methods for manufacturing an adjuvant
EP3638207A1 (de) 2017-06-15 2020-04-22 Infectious Disease Research Institute Nanostrukturierte lipidträger sowie stabile emulsionen und ihre verwendung
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
CN113631573A (zh) 2019-03-25 2021-11-09 国家医疗保健研究所 通过靶向新Tau物种治疗Tau蛋白病的方法
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
US11655290B2 (en) 2021-06-17 2023-05-23 Atreca, Inc. Anti-CSP antibodies
EP4169513A1 (de) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Hilfsstoffzusammensetzung enthaltend sting agonisten
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584866D1 (de) * 1984-09-12 1992-01-23 Chiron Corp Hybridpartikel-immunogene.
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
EP0278940A3 (de) * 1987-01-30 1988-12-07 Smithkline Biologicals S.A. Hepatitis-B-Virus-Oberflächenantigene und sie enthaltende hybride Antigene
US4886782A (en) * 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
EP0300213A1 (de) * 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Virale, immunogen wirksame Peptidpartikel von Hepatitis A
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5028425A (en) * 1988-07-07 1991-07-02 The United States Of America As Represented By The Department Of Health And Human Services Synthetic vaccine against P. falciparum malaria

Also Published As

Publication number Publication date
PT101052A (pt) 1994-01-31
MX9206574A (es) 1993-05-01
DE69228698D1 (de) 1999-04-22
JP3954643B2 (ja) 2007-08-08
HK1012405A1 (en) 1999-07-30
SG48390A1 (en) 1998-04-17
EP0614465A1 (de) 1994-09-14
EP0614465B1 (de) 1999-03-17
CA2123612C (en) 2002-06-25
JPH07501213A (ja) 1995-02-09
ATE177755T1 (de) 1999-04-15
AU2927892A (en) 1993-06-15
NZ245114A (en) 1995-07-26
GR3029717T3 (en) 1999-06-30
PT101052B (pt) 1999-10-29
CA2123612A1 (en) 1993-05-27
AU712409B2 (en) 1999-11-04
AU1471797A (en) 1997-06-12
KR100251505B1 (ko) 2000-05-01
ES2129461T3 (es) 1999-06-16
WO1993010152A1 (en) 1993-05-27
JP2007209343A (ja) 2007-08-23
DK0614465T3 (da) 1999-09-27
JP4241846B2 (ja) 2009-03-18

Similar Documents

Publication Publication Date Title
DE69228698T2 (de) HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG
DK0835663T3 (da) Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
BR9206131A (pt) Hepatite C: diagnóstico e vacinas
ATE340859T1 (de) Rekombinantes papillomavirus l1 protein
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
LV10726A (lv) Hepatita C virusa diagnostikas lidzekli un vakcinas
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
BR9505739A (pt) Processo para a purificação de um antígeno de superfície viral de hepatite B e vacina viral de hepatite B
DE69232460T2 (de) Die ansteckung blockierende malariaimpfstoffe
FI952171A (fi) Hepatiitti B-pinta-antigeeneille aktiivisten ihmisen monoklonaalisten vasta-aineiden tuotto
EP0542753A4 (en) Epitopes of the pre-s region of hepatitis b virus surface antigen
ZA888580B (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
DE9117146U1 (de) Impfstoffe gegen virale Antigene
ATE177010T1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie
DK146388A (da) Plasmodium falciparum merozoit-overfladeantigen
BR1100913A (pt) Vacinas combinadas compreendendo o antìgeno superficial da hepatite b e outros antìgenos
ZA883365B (en) Newcastle disease virus vaccine and method for the application thereof
DE69033316T2 (de) Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C Virus

Legal Events

Date Code Title Description
R071 Expiry of right

Ref document number: 614465

Country of ref document: EP